![](/images/Email.png)
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataIC50: 92nMAssay Description:NEP inhibitors, such as thiorphan, candoxatril, and candoxatrilat, have been studied as potential therapeutics. Compounds that inhibit both NEP and a...More data for this Ligand-Target Pair
![](/img/powered_by_small.gif)